POPULARITY
3 episodes with Michael R Bishop
3 episodes with Michael R Bishop
3 episodes with Michael R Bishop
3 episodes with Michael R Bishop
3 episodes with Michael R Bishop
3 episodes with Michael R Bishop
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.
Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.
Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.
Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.
Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.
Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.
In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:Optimal use of approved CAR T-cell therapies for lymphoma and ALLInvestigational CAR T-cell therapies for multiple myelomaManaging CAR T-cell therapy–related toxicitiesPresenters:Michael R. Bishop, MDProfessor of MedicineSection of Hematology/OncologyDirector, Cellular Therapy ProgramUniversity of ChicagoChicago, IllinoisDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief, Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, MassachusettsNoopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.Link to full program:https://bit.ly/3iyt5zQ
Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy. Upon completion of this activity, participants should be better able to: Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies, Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma, Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia
Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy. Upon completion of this activity, participants should be better able to: Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies, Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma, Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia
Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy. Upon completion of this activity, participants should be better able to: Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies, Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma, Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia
Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy. Upon completion of this activity, participants should be better able to: Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies, Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma, Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia
Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy. Upon completion of this activity, participants should be better able to: Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies, Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma, Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia
Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy. Upon completion of this activity, participants should be better able to: Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies, Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma, Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia
© 2020-2026 Ivy Podcast Discovery LLC
